Join Paid Clinical Trials for Chronic Illness in Canada

Paid Clinical Trials and Focus Groups by Category

All Categories ... by Medical Condition » ... Chronic Illness » ... **Canada

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo; Drug: Tiotropium
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Eccentric Exercise Training as Novel Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic; Emphysema
Intervention: Other: Eccentric exercise training
Sponsors: McGill University; McGill University Health Center
Recruiting - verified December 2009
The Electronic Asthma Action Plan System for Implementation in Primary Care

Condition: Asthma
Intervention: Other: Electronic Asthma Action Plan System
Sponsor: St. Michael's Hospital, Toronto
Not yet recruiting - verified February 2010
Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: olodaterol (BI 1744) low and placebo; Drug: olodaterol (BI 1744) low and low tio; Drug: olodaterol (BI 1744) high and placebo; Drug: olodaterol (BI 1744) low and medium tio; Drug: olodaterol (BI 1744) low and high tio; Drug: olodaterol (BI 1744) high and low tio; Drug: olodaterol (BI 1744) high and medium tio; Drug: olodaterol (B( 1744) high and high tio
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Effect of Treatment BI 1744 CL (5 and 10 Mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Olodaterol (BI 1744); Drug: Olodaterol (BI 1744); Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Effect of Treatment BI 1744 CL (5 and 10 Mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Olodaterol (BI 1744); Drug: Olodaterol (BI 1744); Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GW642444 Inhalation Powder; Drug: FF/GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps)

Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsor: Abbott
Recruiting - verified January 2010

Join Paid Clinical Trials for Chronic Illness in Canada - Clinical Trials

Join Paid Clinical Trials for Chronic Illness in Canada

Paid Clinical Trials and Focus Groups by Category

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials